Strategic Financial Concepts LLC Makes New Investment in Stryker Co. (NYSE:SYK)

Strategic Financial Concepts LLC acquired a new stake in shares of Stryker Co. (NYSE:SYK) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 154,893 shares of the medical technology company’s stock, valued at approximately $55,769,000. Stryker comprises about 1.7% of Strategic Financial Concepts LLC’s investment portfolio, making the stock its 3rd largest position.

A number of other institutional investors have also made changes to their positions in SYK. Dunhill Financial LLC grew its holdings in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 37 shares during the last quarter. Darwin Wealth Management LLC bought a new stake in shares of Stryker during the 3rd quarter worth $36,000. Activest Wealth Management acquired a new position in Stryker in the 4th quarter valued at $36,000. Crews Bank & Trust bought a new position in Stryker in the 4th quarter worth $39,000. Finally, Hara Capital LLC acquired a new position in Stryker during the 3rd quarter worth $42,000. 77.09% of the stock is owned by institutional investors.

Stryker Trading Down 0.9 %

Shares of SYK opened at $385.05 on Friday. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The stock has a market cap of $146.79 billion, a PE ratio of 49.62, a PEG ratio of 2.98 and a beta of 0.96. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The stock has a 50 day simple moving average of $377.31 and a 200-day simple moving average of $366.66.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the company earned $3.46 earnings per share. On average, sell-side analysts predict that Stryker Co. will post 13.49 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.87%. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

SYK has been the topic of several research analyst reports. Stifel Nicolaus raised their price target on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Canaccord Genuity Group lifted their price target on Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. JPMorgan Chase & Co. increased their price objective on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 target price on shares of Stryker in a research report on Wednesday, January 29th. Finally, Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $370.00 to $445.00 in a report on Monday, December 2nd. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average target price of $420.68.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.